暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股市場個股詳情
ICCM Icecure Medical
- 1.200
- +0.010+0.84%
收盤價 04/26 16:00 (美東)
- 1.200
- 0.000-0.02%
盤後 18:25 (美東)
5487.56萬總市值-3750市盈率TTM
1.218最高價1.180最低價6.06萬股成交量1.210今開1.190昨收7.23萬成交額0.32%換手率虧損市盈率(靜)4572.97萬總股本1.57052周最高4.51市淨率2268.41萬流通值0.52052周最低--股息TTM1890.34萬流通股16.000歷史最高--股息率TTM3.21%振幅0.520歷史最低1.193平均價1股每手
全部分時
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
分析師對醫療保健公司發表見解：Icecure Medical（ICCM）、Viracta Therapeutics（VIRX）和Bioxcel Therapeutics（BTAI）
IceCure Medical宣佈即將舉行的股東大會
IceCure Medical 獲得 FDA 批准，試驗結果令人鼓舞
IceCure Medical 尋求 FDA 批准 ProSense 治療早期乳腺癌
IceCure Medical（ICCM）表示，它已向美國食品藥品監督管理局提交了最終數據，尋求ProSense的上市許可，用於治療早期T1浸潤性乳腺癌患者
快訊 | Icecure 醫療報告最終的 Ice3 乳腺癌冷凍消融試驗結果爲患者和醫生滿意度爲 100%，無複發率爲 96.3%：提交給美國食品藥品管理局申請上市許可以治療早期乳腺癌的數據
IceCure醫療報告ICE3乳腺癌冷凍消融試驗的最終結果爲患者和醫生滿意度爲100％，無複發率爲96.3％：已提交給美國食品藥品管理局申請上市許可以治療早期乳腺癌的數據
理查德·芬博士在極具影響力的美國乳腺外科學會（“ASBR”）年會上發表的數據獲得了由乳腺外科醫生投票的科學影響獎。
評論
interesting movement
$Icecure Medical(ICCM.US$
Is this just me? Or is it quite odd the price keeps dropping despite the good news?
Not neccessarily dropping but it keeps going up and down.
Shorts sellers trying to bury the stock? I’m not sure! Anyone able to answer my question?
Is this just me? Or is it quite odd the price keeps dropping despite the good news?
Not neccessarily dropping but it keeps going up and down.Shorts sellers trying to bury the stock? I’m not sure! Anyone able to answer my question?
$Icecure Medical(ICCM.US$ buy the dip!!
2
$Icecure Medical(ICCM.US$ why drop?
Medical Device Company Seeks FDA Approval For Promising Breast Cancer Treatment
IceCure Medical's Breakthrough in Breast Cancer Treatment: A Beacon of Hope.
In an era where the fight against breast cancer sees continuous battles, a significant development emerges from IceCure Medical Ltd., promising a new dawn in the treatment of early-stage breast cancer. The company recently announced the final results of its ICE3 trial, which could potentially revolutionize how we approach breast cancer treatm...
In an era where the fight against breast cancer sees continuous battles, a significant development emerges from IceCure Medical Ltd., promising a new dawn in the treatment of early-stage breast cancer. The company recently announced the final results of its ICE3 trial, which could potentially revolutionize how we approach breast cancer treatm...
$Icecure Medical(ICCM.US$ 96.3% Recurrence free rate is a feat for this breast cancer treatment. Yet again, people didnt really put notice on this even if 30% of all diagnosed cancers in women is breast cancer.
4
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅